Showing results (11-20 of 172) with videos related to

Sort By:
Pageof 18
Biochemical and Biophysical Research Communications|September 16, 1985
Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cellsR Ganapathi, D Grabowski, H Schmidt, et al.
Molecular Pharmacology|January 1, 1991
Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cellsR Ganapathi, T Kuo, L Teeter, et al.
Biochemical and Biophysical Research Communications|May 14, 1993
Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cellsR Ganapathi, L Zwelling, A Constantinou, et al.
British Journal of Cancer|September 1, 1988
Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistanceR Ganapathi, H Schmidt, D Grabowski, et al.
Cancer Research|November 1, 1986
Modulation of adriamycin and N-trifluoroacetyladriamycin-14-valerate induced effects on cell cycle traverse and cytotoxicity in P388 mouse leukemia cells by caffeine and the calmodulin inhibitor trifluoperazineR Ganapathi, D Grabowski, H Schmidt, et al.
British Journal of Cancer|December 1, 1989
N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivoR Ganapathi, D Grabowski, T W Sweatman, et al.
British Journal of Cancer|January 1, 1996
Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cellsK I Kawamura, D Grabowski, K Weizer, et al.
Biochemical Pharmacology|June 15, 1991
Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cellsR Ganapathi, N Kamath, A Constantinou, et al.
Cancer Communications|January 1, 1989
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavageR Ganapathi, D Grabowski, J Ford, et al.
Biochemical Pharmacology|September 1, 1992
Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantroneN Kamath, D Grabowski, J Ford, et al.
Pageof 18